Breaks Categories: News

FridayJan 13, 2023 10:32 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) CEO Reports on Company Accomplishments, Outlook through Shareholder Letter

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and NFTs, and JUPW’s SRM Entertainment division submitting a confidential registration statement to the SEC on a key step on its journey to becoming an independently traded NASDAQ company. The letter also noted that Jupiter Wellness…

Continue Reading

ThursdayJan 12, 2023 1:11 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian Medical University (“PUM”) in Szczecin, Poland. “Based on the data seen to date, Berubicin has continued to demonstrate an overall safety profile more favorable than other known anthracyclines and we remain encouraged by its potential.…

Continue Reading

ThursdayJan 12, 2023 10:51 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Traders News Source Interview

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies. Branislav Vajdic, PhD, CEO and founder of HeartBeam joined Traders News Source’s Toni Loudenbeck to provide an overview of HeartBeam and discuss the potential for the company’s innovative AIMI(TM) and AIMIGo(TM) technology. In the interview, Dr. Vajdic shares his background and vision leading up to the company’s 12-lead standard…

Continue Reading

ThursdayJan 12, 2023 10:35 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent,” said Cybin CEO Doug Drysdale. “Since the pandemic, the prevalence of depression and…

Continue Reading

WednesdayJan 11, 2023 9:57 am

BioMedNewsBreaks — MetAlert Inc. (MLRT), TrakTec Sign Heads of Terms Agreement for Upcoming Acquisition

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, signed a Heads of Terms agreement with TrakTec outlining details about the previously announced acquisition. The agreement noted that MLRT would acquire the location-awareness technology company in a cash and stock deal worth $4.5 million. The agreement also notes that the acquisition should be closed on or before March 17, 2023, and will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile app. In addition, the agreement noted that key hires would include board…

Continue Reading

TuesdayJan 10, 2023 1:49 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured on ‘Gametime with Sequire’

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in a recent interview with Sequire Spotlight. In the program, MetAlert’s CEO Patrick Bertagna joined Host Carmel Fisher to discuss the company’s business model and goals heading into the near future. “We’re a medical device/technologies company. We cater to a specific segment of the population – people with cognitive memory disorders such as Alzheimer’s, dementia, autism, traumatic brain injury,” Bertagna said. “And most of these people can’t use conventional type of technologies. So, we’ve developed a suite of products and…

Continue Reading

TuesdayJan 10, 2023 11:48 am

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate, CycloSam, to treat cancer that has either originated in the bone or has metastasized to the bone from the breast, prostate, lung or other organs. During 2022, CycloSam received rare pediatric disease designation for the…

Continue Reading

TuesdayJan 10, 2023 11:35 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

Continue Reading

TuesdayJan 10, 2023 10:53 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, announced that today at 10 a.m. EST, the company will start trading on Upstream under the ticker symbol JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company noted that a digital collectible NFT commemorating the dual listing would be available for Upstream participants to claim using the code: JUPW. Through Upstream, investors around the world can invest in JUPW by downloading the Upstream app from their preferred app store and creating an account. Transactions…

Continue Reading

MondayJan 09, 2023 11:56 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

Continue Reading